--- title: "Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/000766.SZ.md" symbol: "000766.SZ" name: "Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd" industry: "Pharmaceuticals" datetime: "2026-03-14T06:55:39.356Z" locales: - [en](https://longbridge.com/en/quote/000766.SZ.md) - [zh-CN](https://longbridge.com/zh-CN/quote/000766.SZ.md) - [zh-HK](https://longbridge.com/zh-HK/quote/000766.SZ.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/000766.SZ.md) | [繁體中文](https://longbridge.com/zh-HK/quote/000766.SZ.md) # Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ) ## Company Overview Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. Its products covers anti-tumor, microbial, cardiovascular, heat-clearing and detoxification, digestive system, skeletal muscle system, gynecological system, nervous system, and other fields. The company also provides bone peptides, protective chemical medicines, cardiovascular and cerebrovascular chinese patent medicines, heat-clearing and detoxifying medicines, and children's respiratory system chinese patent medicines; and Xiaojin pills, Tian Ranshexiang Xiaojin pills, Xiaokechuan capsules, Jiuwei Qianghuo granules, Xiongdan powder, Bear Bile powder, and Wenweishu tablets to treat glandular hyperplasia, inflammatory diseases, bone trauma and soft tissue injury, and other related diseases. In addition, the company offers bacillus cereus live bacteria capsules, bacillus cereus live bacteria tablets are therapeutic live bacteria microecological preparations to treat enteritis, diarrhea, infantile diarrhea, and intestinal dysfunction. | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Exchange | CN Market | | Website | [www.thjm.cn](https://www.thjm.cn) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: C > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-03-14T04:30:12.000Z **Overall: C (0.56)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 85 / 222 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: C #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -10.84% | | | Net Profit YoY | 9.88% | | | P/B Ratio | 8.83 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 20324791913.69 | | | Revenue | 1246183392.25 | | #### Multi Score Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 2.48% | C | | Profit Margin | 4.61% | C | | Gross Margin | 70.66% | A | | Revenue YoY | -10.84% | D | | Net Profit YoY | 9.88% | C | | Total Assets YoY | -1.53% | D | | Net Assets YoY | -1.74% | D | | Cash Flow Margin | 2168.20% | A | | OCF YoY | -10.84% | D | | Turnover | 0.27 | D | | Gearing Ratio | 49.17% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-10.84%", "rating": "" }, { "name": "Net Profit YoY", "value": "9.88%", "rating": "" }, { "name": "P/B Ratio", "value": "8.83", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "20324791913.69", "rating": "" }, { "name": "Revenue", "value": "1246183392.25", "rating": "" } ] }, { "name": "Multi Score", "grade": "C", "indicators": [ { "name": "ROE", "value": "2.48%", "rating": "C" }, { "name": "Profit Margin", "value": "4.61%", "rating": "C" }, { "name": "Gross Margin", "value": "70.66%", "rating": "A" }, { "name": "Revenue YoY", "value": "-10.84%", "rating": "D" }, { "name": "Net Profit YoY", "value": "9.88%", "rating": "C" }, { "name": "Total Assets YoY", "value": "-1.53%", "rating": "D" }, { "name": "Net Assets YoY", "value": "-1.74%", "rating": "D" }, { "name": "Cash Flow Margin", "value": "2168.20%", "rating": "A" }, { "name": "OCF YoY", "value": "-10.84%", "rating": "D" }, { "name": "Turnover", "value": "0.27", "rating": "D" }, { "name": "Gearing Ratio", "value": "49.17%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 353.63 | 154/222 | 448.80 | 396.67 | 337.21 | | PB | 8.83 | 209/222 | 11.34 | 10.33 | 8.55 | | PS (TTM) | 16.31 | 203/222 | 20.63 | 18.16 | 14.61 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A | | 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B | | 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B | | 04 | Salubris (002294.SZ) | B | B | C | A | B | B | | 05 | Haisco (002653.SZ) | B | C | B | C | B | B | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000766.SZ/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000766.SZ/norm.md) - [Related News](https://longbridge.com/en/quote/000766.SZ/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000766.SZ/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**